Altimmune ((ALT)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Altimmune, Inc. is currently recruiting for the RESTORE TRIAL, a Phase 2 study aimed at evaluating the efficacy and safety of Pemvidutide in treating Alcohol-Associated Liver Disease (ALD). This study is significant as it targets a prevalent liver condition linked to alcohol consumption, with the potential to offer a new therapeutic option for patients.
The intervention being tested is Pemvidutide, administered as a 2.4 mg subcutaneous injection once weekly. A placebo group is also included for comparison, ensuring the study’s robustness.
The study design is interventional, with participants randomly assigned to either the Pemvidutide or placebo group. It follows a parallel model and employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose of this study is treatment-focused.
The trial officially started on June 16, 2025, with the latest update submitted on July 8, 2025. These dates mark the beginning of participant recruitment and the most recent information available, respectively, indicating the study’s active status.
For investors, this update could influence Altimmune’s stock performance positively, as successful trial outcomes may enhance the company’s market position in the liver disease treatment sector. The study’s progress is crucial, given the competitive landscape of pharmaceutical advancements targeting liver conditions.
The RESTORE TRIAL is ongoing, with further details accessible on the ClinicalTrials portal.